APC and adenoma: Effective targeted therapies are now available for some of the affected signaling pathways, such as the NSAIDs sulindac and celecoxib that significantly reduce adenoma load in patients with APC germline mutations, probably because of the typical inhibition of the WNT/β-catenin signaling pathway.